Methylphenidate for the treatment of Parkinson disease and other neurological disorders

Eitan Auriel, Jeffrey M. Hausdorff, Nir Giladi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Methylphenidate (MPH) is a central nervous system stimulant derived from an amphetamine and acts as a potent inhibitor of catecholamine reuptake and increases dopamine levels in the brain. Methylphenidate is widely used for the treatment of children and adults with attention deficit hyperactivity disorder. Because the dopaminergic system is critical to the pathological process in Parkinson disease (PD), it has been suggested that MPH, which increases dopaminergic stimulation at the postsynaptic receptor level, may provide symptomatic relief in PD patients. This article reviews those studies that have evaluated the potential of MPH to treat the motor and cognitive aspects of PD, summarizes the evidence for clinical use in other neurological diseases, and briefly reviews the physiological mechanisms whereby MPH may bring about its therapeutic effects. Methylphenidate does seem to be useful for ameliorating cognitive, affective, and motor deficits in PD and in other neurological patients; however, additional studies are needed before MPH can be routinely prescribed as an adjunct therapy in these populations.

Original languageEnglish
Pages (from-to)75-81
Number of pages7
JournalClinical Neuropharmacology
Issue number2
StatePublished - Mar 2009


  • Gait
  • Methylphenidate
  • Parkinson disease


Dive into the research topics of 'Methylphenidate for the treatment of Parkinson disease and other neurological disorders'. Together they form a unique fingerprint.

Cite this